KPV vs PNC27
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Lys-Pro-Val, Alpha-MSH fragment
A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
Also: PNC-27, p53-HDM2 Disruptor Peptide
A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | KPV | PNC27 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | KPV retains the anti-inflammatory properties of α-MSH without melanocortin receptor activation. It inhibits inflammatory pathways including NF-κB, reduces pro-inflammatory cytokines, and has antimicrobial properties. | PNC27 contains two functional domains: residues 12-26 of the p53 HDM-2 binding domain on the N-terminus, and a membrane residency peptide (MRP/penetratin) on the C-terminus. Cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells do not. PNC27 binds to this membrane-bound HDM-2, adopts an alpha-helical conformation similar to p53, and induces transmembrane pore formation. This causes extrusion of intracellular contents and rapid necrotic cell death. The peptide also enters cancer cells and disrupts mitochondrial membranes. Importantly, this mechanism is independent of intracellular p53 status - effective even in p53-null cancers. |
| Common Dosing | 200-500 mcg daily 1-2x daily | No human dose - research compound only Not applicable - no human use |
| Administration | Subcutaneous injection or oral (capsules) | IV injection in animal studies - not for human use |
| Typical Duration | 4-8 weeks typical | Research protocols only - no human use data |
| Best Time to Take | Morning or as directed | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show effectiveness in inflammatory bowel disease models. Research demonstrates wound healing acceleration and antimicrobial activity. Being investigated for gut health and inflammatory conditions. | Extensive in vitro research demonstrates PNC27 selectively kills multiple cancer cell types including breast (MCF-7), pancreatic (MIA-PaCa-2), cervical (HeLa, SW756), ovarian (OVCAR-3, OV-90), colon, lung, and leukemia (K562, U937, HL-60) cell lines. Effective concentration: 0.1-0.2 mg/mL kills most cancer cells. At 0.3 mg/mL, nearly 100% of K562 leukemia cells were killed. Studies confirm no toxicity to normal cells including fibroblasts and leukocytes. Mechanism involves membrane pore formation and necrosis (not apoptosis). Research published in PNAS and multiple peer-reviewed journals. |
Frequently Asked Questions: KPV vs PNC27
What is the difference between KPV and PNC27?
KPV is a immune peptide that a tripeptide derived from alpha-melanocyte stimulating hormone (α-msh). known for potent anti-inflammatory effects, particularly in the gut. PNC27 is a immune peptide that a chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. selectively kills cancer cells by binding to hdm-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected. The main differences lie in their mechanisms of action and clinical applications.
Which is better, KPV or PNC27?
Neither is universally "better" - the choice depends on your specific goals. KPV is typically used for immune purposes, while PNC27 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can KPV and PNC27 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using KPV and PNC27 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of KPV and PNC27 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.